@suboxoneshawty I used to never have allergies aside from springtime, now I’ve noticed it not quite year round but significantly more than usual. No clue what the cause is for me but it’s fuckin annoying.
@alphaporgs@AaronRosenblum5@Caleb_Crann I agree clinical trial wise they definitely have the upper hand.However I was reading usona former chief medical officer is now the director of cder. Obviously could be a conflict of interest there and with the reporting they had a hand in lykos getting denied it would suprise me
@alphaporgs@AaronRosenblum5@Caleb_Crann Millions using multiple year long patented polymorphs. Not saying it’s impossible just saying it seems pretty unlikely. I think they will both succeed in the end as it’s different markets and majorly different orgs.
@alphaporgs@AaronRosenblum5@Caleb_Crann Usona’s formulation… they have not published which form/ polymorph they are using in trials, so to say they will infringe on hyper specific patents is a far stretch imo. I say this as a long time CMPS holder, Compass will struggle getting an injunction unless Usona spent -
@alphaporgs@AaronRosenblum5@Caleb_Crann Yes brother I am familiar with all of the Compass patents related to psilocybin, probably been following since IPO... With that knowledge and all that is public I am asking you what specifically in their patents do you see that would be infringement?
@alphaporgs@AaronRosenblum5@Caleb_Crann Genuinely curious what patent do you think Compass has that would stop Usona? They could potentially slow them down but don’t see any of their patents being strong enough to straight up prevent them from going to market.